Home2018-12-05T20:44:49+00:00

Access to Hemlibra

The CHS asks members of the bleeding disorder community for help in getting access to Hemlibra for patients with FVIII inhibitors.
Current delays are unacceptable.

LEARN MORE

Hemophilia Today

Check out the latest issue of the CHS’ newsmagazine, Hemophilia Today, for information, current news and issues relevant to the bleeding disorder community.

LEARN MORE

Research

The Canadian Hemophilia Society (CHS) is pleased to put out a special call for applications for two of its research programs for the 2019-2020 grant period: the CHS/Novo Nordisk Psychosocial Research Program and the CHS – Bayer – ADVANCE Canada Research Program. Deadline: FEBRUARY 8, 2019

LEARN MORE

Support us

Donations enable us to work to improve lives of people affected by bleeding disorders. Every gift makes a difference. Thank you!

LEARN MORE

STRATEGIC PLAN  |  2016‐2020

LEARN MORE

CHS 2017 Annual Report

The year 2017 was a remarkable one. Together, we have made noteworthy advancements
towards our vision for the inherited bleeding disorder community.

Read the report here.

Q&A about RFPs

We often receive questions about the tender process (RFP) for clotting factor concentrates. We produced a Q&A document which we hope will answer all your questions on the topic.

Learn more

Recombinant factor concentrate charts

Please check out our updated charts listing the recombinant factor concentrates and their description.

Click here for the rFVIII chart

Click here for the rFIX chart

REACH US AT

1-800-668-2686

chs@hemophilia.ca

WE’RE HERE TO HELP.

CONTACT US

FIND A TREATMENT CENTRE NEAR YOU

SEARCH
Do NOT follow this link or you will be banned from the site!